{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:03:53Z","timestamp":1789621433680,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clinthera.2026.08.013","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:32:15Z","timestamp":1789619535000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Medical Device Safety Throughout the Product Lifecycle: Regulatory Frameworks, Digital Transformation, and the Role of Artificial Intelligence in Devices and Monitoring"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2493-034X","authenticated-orcid":false,"given":"Shabnam","family":"Vaezzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Oyesile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Pakkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.08.013_bib0001","unstructured":"Wohlfarth A. Life science industry explained: a comprehensive guide. 2024. Available from: https:\/\/www.ourcrowd.com\/learn\/life-science-industry-explained-a-comprehensive-guide. Accessed May 22, 2026"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0002","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40264-025-01599-6","article-title":"Navigating medical device safety: current status, challenges, and future regulatory directions","volume":"49","author":"Aimer","year":"2026","journal-title":"Drug Saf"},{"issue":"10","key":"10.1016\/j.clinthera.2026.08.013_bib0003","article-title":"Improving adverse drug event reporting by healthcare professionals","volume":"10","author":"Shalviri","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0004","unstructured":"FDA_US Food and Drug Administration. Human factors: postmarket information\u2014device surveillance and reporting processes. 2018."},{"key":"10.1016\/j.clinthera.2026.08.013_bib0005","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Guideline for good clinical practice E6(R3). 2025."},{"key":"10.1016\/j.clinthera.2026.08.013_bib0006","series-title":"ICH harmonised tripartite guideline. Clinical safety data management: Definitions and standards for expedited reporting E2A (Current Step 4 version)","year":"1994"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0007","series-title":"European Commission (Directorate-General for Health and Food Safety); [cited 2026 Sep 12]","article-title":"MDCG 2020-10\/1 Rev. 1 \u2013 Guidance on safety reporting in clinical investigations of medical devices under the Regulation (EU) 2017\/745 [Internet]","year":"2022"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0008","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s43441-023-00514-4","article-title":"Materiovigilance in perspective: understanding its concept and practice in the global healthcare system","volume":"57","author":"Sapkota","year":"2023","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.apergo.2022.103769","article-title":"Usability challenges in the use of medical devices in the home environment: a systematic review of literature","volume":"103","author":"Tase","year":"2022","journal-title":"Appl Ergon"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0010","series-title":"Medical devices\u2014application of risk management to medical devices","first-page":"36","year":"2019"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0011","unstructured":"ISO 10993-17. International Standard Organization. 2023. Biological evaluation of medical devices. Available from: https:\/\/www.iso.org\/standard\/75323.html. Accessed May 25, 2026."},{"key":"10.1016\/j.clinthera.2026.08.013_bib0012","unstructured":"IEC 62366-1. International Standard Organization. 2021. Application of usability engineering to medical devices. Available from: https:\/\/www.iso.org\/standard\/63179.html. Accessed May 25, 2026."},{"key":"10.1016\/j.clinthera.2026.08.013_bib0013","unstructured":"International Organization for Standardization. ISO 13485 medical devices. 2025. Available from: https:\/\/www.iso.org\/iso-13485-medical-devices.html. Accessed May 22, 2026."},{"key":"10.1016\/j.clinthera.2026.08.013_bib0014","unstructured":"ISO 14155. International Standard Organization. 2026. Clinical investigation of medical devices for human subjects\u2014good clinical practice. Available from: https:\/\/www.iso.org\/standard\/83968.html. Accessed May 25, 2026."},{"key":"10.1016\/j.clinthera.2026.08.013_bib0015","unstructured":"Code of Federal Regulations. FDA. 2026. good laboratory practice for nonclinical laboratory studies. Available from: https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-A\/part-58. Accessed May 23, 2026."},{"key":"10.1016\/j.clinthera.2026.08.013_bib0016","series-title":"NAMSA Resources Blog","article-title":"Guide to understanding FDA preclinical study requirements for medical devices","author":"Clermont","year":"2025"},{"issue":"1","key":"10.1016\/j.clinthera.2026.08.013_bib0017","doi-asserted-by":"crossref","DOI":"10.1111\/wrr.13232","article-title":"The wound reporting in animal and human preclinical studies guidelines","volume":"33","author":"Ojeh","year":"2025","journal-title":"Wound Repair Regen"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0018","doi-asserted-by":"crossref","first-page":"f3012","DOI":"10.1136\/bmj.f3012","article-title":"IDEAL framework for surgical innovation 1: the idea and development stages","volume":"346","author":"McCulloch","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0019","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/SLA.0000000000004907","article-title":"IDEAL-D framework for device innovation","volume":"275","author":"Marcus","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0020","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/pharmaceutics5010094","article-title":"Safety monitoring in clinical trials","volume":"5","author":"Yao","year":"2013","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0021","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/17407745231203391","article-title":"Statistical rules for safety monitoring in clinical trials","volume":"21","author":"Martens","year":"2024","journal-title":"Clin Trials"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0022","series-title":"Decentralized Clinical Trials: Recommendations. Durham, NC","year":"2024"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0023","unstructured":"U.S. Food and Drug Administration. Conducting clinical trials with decentralized elements: guidance for industry, investigators, and other interested parties. Silver Springs, MD: U.S. Department of Health and Human Services 2024. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/conducting-clinical-trials-decentralized-elements."},{"key":"10.1016\/j.clinthera.2026.08.013_bib0024","series-title":"Recommendation Paper on Decentralised Elements in Clinical Trials","year":"2025"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0025","unstructured":"FDA. FDA. 2024. Conducting clinical trials with decentralized elements. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/conducting-clinical-trials-decentralized-elements. Accessed May 23, 2026"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0026","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/cpt.966","article-title":"Wearable devices in clinical trials: hype and hypothesis","volume":"104","author":"Izmailova","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0027","unstructured":"Veeva Systems. About the safety-EDC connection | Veeva vault help. 2025. Available from: https:\/\/platform.veevavault.help\/en\/lr\/679350\/ Accessed Apr 29, 2026"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0028","doi-asserted-by":"crossref","unstructured":"CIOMS. Patient involvement in the development, regulation and safe use of medicines. Geneva; 2022. doi:10.56759\/iiew8982","DOI":"10.56759\/iiew8982"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0029","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.cct.2011.05.008","article-title":"Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information","volume":"32","author":"Ball","year":"2011","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0030","series-title":"Data and Safety Monitoring Committees in Clinical Trials","author":"Herson","year":"2016"},{"issue":"9","key":"10.1016\/j.clinthera.2026.08.013_bib0031","article-title":"The essential role of medical monitors in clinical trials","volume":"17","author":"Klein","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0032","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/biomet\/64.2.191","article-title":"Group sequential methods in the design and analysis of clinical trials","volume":"64","author":"Pocock","year":"1977","journal-title":"Biometrika"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0033","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2307\/2533377","article-title":"Practical Bayesian guidelines for phase IIB clinical trials","volume":"50","author":"Thall","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0034","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s43441-019-00022-4","article-title":"Impact of design on medical device safety","volume":"54","author":"Micl\u0103u\u015f","year":"2020","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0035","unstructured":"Tartal J. FDA. Design controls. Available from: www.fda.gov\/media\/116762\/download Accessed May 22, 2026"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0036","unstructured":"Tartal J. FDA. Risk basics for medical devices. Available from: www.fda.gov\/media\/163912\/download Accessed May 22, 2026."},{"key":"10.1016\/j.clinthera.2026.08.013_bib0037","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/17434440.2025.2517168","article-title":"Methodologies for the benefit\u2013risk analysis of medical devices: a systematic review","volume":"22","author":"Freyer","year":"2025","journal-title":"Expert Rev Med Devices"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0038","unstructured":"European Commission. European Commission. 2025. European Commission Proposal for Regulation of the European Parliament and of the Council. Available from: https:\/\/www.europarl.europa.eu\/RegData\/docs_autres_institutions\/commission_europeenne\/com\/2025\/1023\/COM_COM(2025)1023_EN.pdf Accessed Jul 19, 2026"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0039","unstructured":"FDA. FDA. 2020. Postmarketing surveillance programs. Available from: https:\/\/www.fda.gov\/drugs\/surveillance-post-drug-approval-activities\/postmarketing-surveillance-programs. Accessed Jul 28, 2026."},{"key":"10.1016\/j.clinthera.2026.08.013_bib0040","unstructured":"FDA. FDA. 2026. FDA announces major steps to implement real-time clinical trials. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-announces-major-steps-implement-real-time-clinical-trials. Accessed May 23, 2026."},{"key":"10.1016\/j.clinthera.2026.08.013_bib0041","unstructured":"FDA. FDA. 2022. Procedures for handling post-approval studies imposed by premarket approval application order. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/procedures-handling-post-approval-studies-imposed-pma-order. Accessed Jul 28, 2026."},{"key":"10.1016\/j.clinthera.2026.08.013_bib0042","doi-asserted-by":"crossref","first-page":"7648","DOI":"10.34172\/ijhpm.2023.7648","article-title":"Quality and utility of European cardiovascular and orthopaedic registries for the regulatory evaluation of medical device safety and performance across the implant lifecycle: a systematic review","volume":"12","author":"Hoogervorst","year":"2023","journal-title":"Int J Health Policy Manag"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0043","series-title":"Content of premarket submissions for device software functions: guidance for industry and Food and Drug Administration staff","year":"2023"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0044","series-title":"Deciding when to submit a 510(k) for a software change to an existing device: Guidance for industry and Food and Drug Administration staff","year":"2017"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0045","series-title":"Software as a Medical Device (SaMD): Clinical Evaluation (IMDRF\/SaMD WG\/N41FINAL)","year":"2017"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0046","unstructured":"FDA. FDA. 2025. Artificial intelligence-enabled device software functions: lifecycle management and marketing submission recommendations."},{"key":"10.1016\/j.clinthera.2026.08.013_bib0047","series-title":"Cybersecurity in Medical Devices Quality Management Considerations and Content of Premarket Submissions: Guidance for Industry and Food and Drug Administratiioin Satt","year":"2026"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0048","doi-asserted-by":"crossref","DOI":"10.1038\/s41746-020-00324-0","article-title":"The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online database","volume":"3","author":"Benjamens","year":"2020","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2024.171672","article-title":"Digital technologies to unlock safe and sustainable opportunities for medical device and healthcare sectors with a focus on the combined use of digital twin and extended reality applications: a review","volume":"926","author":"Rowan","year":"2024","journal-title":"Sci Total Environ"},{"key":"10.1016\/j.clinthera.2026.08.013_bib0050","unstructured":"FDA.FDA.2025.Artificial Intelligence-Enabled Medical Devices. https:\/\/fda.gov\/medical-devices-samd\/artificial-inelligence-enabled-medical-devices. Accessed May 26, 2026."},{"key":"10.1016\/j.clinthera.2026.08.013_bib0051","unstructured":"IMDRF. International Medical Device Regulators Forum. 2026. Terminologies for categorized adverse event reporting (AER). Available from: https:\/\/www.imdrf.org\/documents\/terminologies-categorized-adverse-event-reporting-aer-terms-terminology-and-codes. Accessed May 23, 2026."},{"key":"10.1016\/j.clinthera.2026.08.013_bib0052","unstructured":"Dezzani L. LinkedIn. 2026. Striving for a world without cancer. Available from: https:\/\/www.linkedin.com\/pulse\/predictions-pharma-medical-affairs-2026-luca-dezzani-o2n2e\/?trackingId=mNCFjYKoTFSiSDCt7EgZiA%3D%3D. Accessed May 22, 2026."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826003140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826003140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:33:01Z","timestamp":1789619581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826003140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":52,"alternative-id":["S0149291826003140"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.08.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Device Safety Throughout the Product Lifecycle: Regulatory Frameworks, Digital Transformation, and the Role of Artificial Intelligence in Devices and Monitoring","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}